ClinicalTrials.gg
Not yet recruitingNCT06141876SUMMIT-90Updated Nov 29, 2023

Evaluation of Psilocybin-Assisted Psychotherapy in Treating Severe Depression in Patients With PTSD

A Phase 2 interventional study of APEX-002-A02 and Placebo in Post-traumatic Stress Disorder and Depression, sponsored by Apex Labs Ltd.. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by Apex Labs Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing psilocybin in Stress Disorders, Post-Traumatic — 13 open to participants now, 16 under way, 3 of them phase 3. Psilocybin · Stress Disorders, Post-Traumatic.

Planned enrollment
3rd of 20
160 · median 33
Started
2023
with 3 others
Phase 2
10 of 20
5 open now
Primary completion
2025-06
later than 1 of 15 live
Registered
8th of 20
by date
Lead sponsor
1 of 20
Apex Labs Ltd.

Among the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, this one is the 3rd largest by planned enrollment, is one of 4 that started in 2023, is one of 10 in phase 2, reaches primary completion later than 1 of the 15 other live ones, and was the 8th registered.

Stress Disorders, Post-Traumatic

2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

13 of the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic are open now, in 5 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

Post-Traumatic Stress Disorder (PTSD) is a mental disorder that may develop in people who have been exposed to a traumatic event, including actual or threatened death, serious injury, or sexual violence. Exposure to a traumatic event is defined as directly experiencing the event, learning about the event, or repeated exposure to details of the event. PTSD is often accompanied by other psychiatric and physical comorbidities, both of which are associated with elevated healthcare costs. Depression, psychosis and suicide rates are consistently reported in greater proportion of PTSD patients. Despite the overwhelming impact of PTSD and comorbid depression, there is a shortfall of effective treatments with few side effects that target the broad range of symptoms, including depression.

Psilocybin has been studied for the treatment of depression, anxiety, tobacco and alcohol use disorders, obsessive-compulsive disorder, end of life depression and anxiety, demonstrating safety and efficacy for a variety of indications, with no significant adverse events occurring during the course of treatment and follow-up. Notably, in a participant group distinguished by long-standing, moderate to severe major depressive disorder, two doses of psilocybin-assisted therapy were found to be as effective in antidepressant effects as 6 weeks of daily escitalopram, a commonly used SSRI. Promising results found in these studies have led to psilocybin recently receiving breakthrough designation from the US FDA for its potential therapeutic effect in the treatment of depression.

Based on previous research, psilocybin has demonstrated a favorable safety profile and has shown preliminary efficacy against depression as well as other symptoms that typically affect patients with PTSD. Unlike traditional SSRIs which are associated with treatment-resistance and addiction, psilocybin requires few doses to improve a wide-range of symptoms and has not been linked with physical dependence. Furthermore, the effect of other psychedelics can vary greatly and may potentially exacerbate existing conditions.

03

Conditions studied

  • Post-traumatic Stress Disorder
  • Depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals between 18 and 65 years of age, inclusive, at the time of consent.
  2. Individuals who are fluent in the language of the study site, specifically English or French.
  3. Meet criteria for current PTSD with presence of symptoms for at least 6 months at screening.
  4. Participant must have at least moderate PTSD, as scored as ≥35 on the CAPS-5 scale at screening.
  5. Participant must have severe depression, as scored as ≥30 on the BDI-II scale at screening.
  6. If individuals are on psychotropic medications, they must be on stable doses (no dosing adjustments/changes for ≥4 weeks) prior to beginning of the study and for the duration of the study.
  7. If individuals are users of psychoactive substances, including alcoholic beverages, tobacco, and cannabis, they must remain on stable doses for the duration of the study.
  8. For individuals of involved in any sexual intercourse that could lead to pregnancy: willing to use adequate to prevent pregnancy (in participant or partner) for the entire duration of the study.
  9. Capable of providing ongoing, signed .
  10. Available for the duration of the study, and able and willing to comply with all study procedures, including completion of questionnaires.
  11. Agree to identify a local contact person to the research team, that is available over the entire course of the subject's participation in the study to act as an emergency contact.

Exclusion criteria

Exclusion Criteria:

  1. Female subject that is pregnant, is planning or suspected to become pregnant, or is lactating.
  2. Known or suspected or to psilocybin or any constituents or of the study drug.
  3. Abnormal and results on the physical examination, vital signs, or laboratory tests at screening.
  4. Presence of any unstable medical condition or neurological illness, in the opinion of the Investigator.
  5. History of clinically significant cardiovascular disease including but not limited to stroke, myocardial infarction or clinically significant arrhythmia (in the past 1 year).
  6. Indication of inadequately treated current hypertension (resting systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg) at screening.
  7. If a subject is being treated with inhibitor(s) of UGT1A9, UGT1A10, monoamine oxidase (MAO), aldehyde dehydrogenase (ALDH), or alcohol dehydrogenase (ADH) they should be discontinued at least five half lives prior to administration of study drug.
  8. Lifetime history of psychosis-related disorder or bipolar disorder (I or II).
  9. Subject has 1st degree relative(s) with schizophrenia or bipolar disorder.
  10. At the time of screening, any condition other than PTSD judged to be the primary presenting psychiatric diagnosis, in the opinion of the Investigator.
  11. Clinical diagnosis of dementia or any physical, cognitive, or language impairment of such severity as to adversely affect the validity of the data derived from the patient reported outcomes.
  12. History of any other clinically significant pulmonary, gastrointestinal, hepatic, renal or any other major concurrent illness that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if he/she takes part in the study.
  13. Individuals who present a current risk to themselves or others, as assessed by the Investigator. This includes, but is not limited to:

    1. Active suicidal ideation with specific plan and intent in the past 1 month, as assessed with the C-SSRS at screening.
    2. History of suicidal behavior (actual attempt, interrupted attempt, aborted or self-interrupted attempt, preparatory acts or behavior) in the past 3 months, as assessed with the C-SSRS at screening.
    3. Any prior suicidal ideation/behavior that, per the Investigator's judgment, makes the participant unsuitable for the study.
  14. Current active Substance Use Disorder or Alcohol Use Disorder, as assessed by the Investigator via medical screening.
  15. Individuals with other personal circumstances and behaviour judged to impact safety (risk and not be able to adhere to the protocol requirements).
  16. Individuals with significant prior exposure to psilocybin, defined as:

    1. Chronic use (>10 exposures) of psilocybin in any form and at any dose in the past year; OR
    2. Any use of psilocybin within 4 weeks prior to screening; OR
    3. Any previous use of psilocybin for PTSD or related symptoms, including depression, that was discontinued due to lack of effect, as judged by the individual or their treating physician.
  17. Self reported use within 12 weeks prior to screening of (i) classical psychedelics other than psilocybin (LSD, mescaline, dimethyltryptamine); (ii) MDMA; (iii) ketamine, and; (iv) dextromethorphan.
  18. Actively participating in other interventional clinical trial(s).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Active

    APEX-002-A02

    Drug: APEX-002-A02

  • Placebo comparator
    Placebo

    matched placebo

    Other: Placebo

Interventions

  • Active

    Also known as: psilocybin

  • OtherPlacebo

    placebo

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Treatment emergent AEs and SAEs

    Time frame: Baseline to Day 140

  2. Number of participants with abnormal vital signs, abnormal physical exam findings, abnormal ECG, and abnormal laboratory tests results

    Measurements: vital signs, physical exam, ECG, and laboratory tests

    Time frame: Baseline to Day 140

  3. Change in severity of depressive symptoms

    Assessed by total score of Beck Depression Inventory (BDI-II); 21-items scale. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.

    Time frame: Baseline to Day 77

Secondary outcomes

  1. Change in severity of depressive symptoms

    Assessed by total score of Beck Depression Inventory (BDI-II); 21-items scale. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.

    Time frame: Baseline to Days 21, 49, and 140

  2. Change in severity of PTSD symptoms

    Assessed by total score of Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (CAPS-5); 30-item questionnaire. Severity rating: 0=absent, 1-mild/sub-threshold, 2-moderate/threshold, 3-severe/markedly elevated, 4-extreme/incapacitating.

    Time frame: Baseline to Days 21, 49, 77 and 140

  3. Change in severity of anxiety

    Assessed by Beck Anxiety Inventory (BAI); 21-item scale. BAI scores are classified as minimal anxiety (0 to 7), mild anxiety (8 to 15), moderate anxiety (16 to 25), and severe anxiety (30 to 63).

    Time frame: Baseline to Days 21, 49, 77 and 140

  4. Change in presence and severity of suicidal ideation and behaviour

    Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS); 10-category scale with binary (yes/no) responses. There are no specified clinical cutoffs for the C-SSRS due to the binary nature of the responses to items. When an item is endorsed ("yes"), the clinician must pose follow-up inquiries to obtain additional information.

    Time frame: Baseline to Days 21, 49, 77 and 140

  5. Change in chronic pain severity

    Assessed by Brief Pain Inventory (BPI); 9-point questionnaire with 0-10 scale for each point; 0=no pain, 10=pain as bad as you can imagine.

    Time frame: Baseline to Days 21, 49, 77 and 140

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2023; primary completion for Jun 2025, 18 months later.

Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's planned 18 months is below that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2023
First posted
Nov 21, 2023
StartEst.
Dec 15, 2023
Primary completionEst.
Jun 15, 2025
CompletionEst.
Jun 15, 2025
Last update
Nov 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06141876
Lead sponsor
Apex Labs Ltd.
Responsible party
Sponsor
First posted
Nov 21, 2023
Start date
Dec 15, 2023 (estimated)
Primary completion
Jun 15, 2025 (estimated)
Completion
Jun 15, 2025 (estimated)
Last update
Nov 29, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion